
Pioneer Institute Launches Tracker Showing Drug Price Controls Are Raising Out-of-Pocket Costs for Medicare Patients
BOSTON--(BUSINESS WIRE)--A new data tool from Pioneer Institute reveals that federal drug price controls—intended to reduce out-of-pocket costs for seniors—are instead making many prescription drugs more expensive for Medicare beneficiaries.
Its first analysis shows that among nine commonly prescribed medications which were subject to price setting by the IRA —used to treat conditions like heart failure, diabetes, and blood clotting—seven saw an increase in patient out-of-pocket costs.
Share
The IRA Medicare Drug Access Tracker, developed by Dr. William Smith and Dr. Robert Popovian, monitors the impact of the Inflation Reduction Act's (IRA) drug pricing provisions. Its first analysis shows that among nine commonly prescribed medications which were subject to price setting by the IRA —used to treat conditions like heart failure, diabetes, and blood clotting— seven saw an increase in patient out-of-pocket costs. (The insulin product was not studied since its price was fixed in statute under a separate IRA provision.)
'The price controls show that Congress fundamentally doesn't understand the rebate system that underpins the pharmaceutical market,' said Dr. William Smith, who built the Tracker with Dr. Robert Popovian. 'All the politicians who argued that the IRA law would make drugs more affordable should look at this new data.'
Under the current system, drug manufacturers pay substantial rebates to pharmacy benefit managers (PBMs) such as Caremark and Optum. These rebates help offset costs but are invisible to patients. When CMS seeks to control prices by lowering a drug's official 'list price,' as it does with the anti-coagulant Eliquis —bringing the price down from $521 to $231—rebates disappear, likely eliminating hundreds of millions in rebate payments from manufacturers to PBMs. PBMs appear to be compensating for that loss by raising co-pays, co-insurance, and transferring other charges directly to patients.
The IRA Medicare Drug Access Tracker focuses on Medicare patients served by the four largest PBMs, which account for 87 percent of the market. The tool is designed to measure whether federal price controls actually improve affordability for seniors by tracking out-of-pocket costs over time. It also follows administrative burdens that PBMs may have imposed on these drugs, which may strain already short-staffed providers, such as requiring them to fill out additional paperwork to secure a prescription (prior authorization) or placing quantity limits on the medications. Such administrative burdens are often used in the industry to discourage demand (demand management).
Among the Tracker's key findings:
Average out-of-pocket costs for the nine drugs rose 32 percent, from $74.51 to $98.42
Seven of the nine drugs saw individual cost increases ranging from $10.56 to $316.81
One of the two medicines seeing no increase in out-of-pocket costs faced competition from biosimilars that only became available in 2025
'Higher out-of-pocket costs are unlikely to be the only unintended consequence of drug price controls,' Dr. Popovian said. 'The IRA also creates less incentive for pharmaceutical innovation and increases the possibility that some popular drugs may be excluded from health insurance formularies.'
This release marks the Tracker's first report. Pioneer Institute will publish additional data later this year, as more drugs fall under the Inflation Reduction Act's price-setting provisions.
The public can find the tool at https://pioneerinstitute.org/rxpricewatch/
Dr. William S. Smith is Senior Fellow & Director of Pioneer Life Sciences Initiative. Dr. Smith has 25 years of experience in government and in corporate roles. His career includes senior staff positions for the Republican House leadership on Capitol Hill, the White House Office of National Drug Control Policy, and the Massachusetts Governor's office where he served under Governors Weld and Cellucci. He spent ten years at Pfizer Inc as Vice President of Public Affairs and Policy where he was responsible for Pfizer's corporate strategies for the U.S. policy environment. He later served as a consultant to major pharmaceutical, biotechnology and medical device companies. Dr. Smith earned his PhD in political science with distinction at The Catholic University of America.
Dr. Robert Popovian is the Founder of the strategic consulting firm Conquest Advisors. He also serves as Chief Science Policy Officer at the Global Healthy Living Foundation, Senior Healthy Policy Fellow at the Progressive Policy Institute, and Visiting Health Policy Fellow at the Pioneer Institute. He previously served as Vice President, U.S. Government Relations at Pfizer.
One of the country's foremost experts on every significant facet of biopharmaceuticals and the healthcare industry, he is a recognized authority on health economics, policy, government relations, medical affairs, and strategic planning. To learn more about Dr. Popovian please click here.
About Pioneer Institute
Pioneer empowers Americans with choices and opportunities to live freely and thrive. Working with state policymakers, we use expert research, educational initiatives, legal action and coalition-building to advance human potential in four critical areas: K-12 Education, Health, Economic Opportunity, and American Civic Values.
Please see below the first group of drugs subject that Pioneer is studying.
Eliquis
Enbrel
Entresto
Farxiga
Imbruvica
Januvia
Jardiance
Stelara
Xarelto
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
19 minutes ago
- Yahoo
PBM lobby sues Arkansas over law requiring drug middlemen to sell pharmacies
This story was originally published on Healthcare Dive. To receive daily news and insights, subscribe to our free daily Healthcare Dive newsletter. The main lobby representing pharmacy benefit managers is suing Arkansas in a bid to stop the state's law preventing the drug middlemen from owning pharmacies. The Pharmaceutical Care Management Association's lawsuit filed Monday in a federal court argues that Arkansas' law — the first of its kind — is unconstitutional and would result in pharmacies closing and medications becoming more difficult for Arkansans to access. It's the latest legal challenge from the PBM industry as it hustles to halt the law and set a precedent that might dissuade other states from passing similar legislation. Arkansas' legislation, called Act 624, is meant to protect local community pharmacies from larger, more diversified chains by requiring companies that own both PBMs and pharmacies to shutter their operations in the state. When signing Act 624 in April, Gov. Sarah Huckabee Sanders said the law was necessary to curb anticompetitive behavior among major PBMs that threatens Arkansas' independent pharmacies. However, PBMs — powerful middlemen that shape interactions and payments between drugmakers, payers and pharmacies — decried the law, arguing it eliminates a significant source of efficiency in the pharmacy supply chain by forcing them to sell off their brick-and-mortar stores and halt mail-order pharmacy operations in the state. The policy would unfairly benefit Arkansas-owned pharmacies at their expense, major PBMs said. Now, the PCMA — which represents 20 PBMs, including the so-called 'Big Three' that control an outsized share of the market — is taking to the courts in an attempt to stop the law before it kicks in at the start of 2026. Arkansas' law will cause roughly 40 PBM-owned pharmacies to close, along with eliminating home delivery options and jeopardizing access to specialty drugs for patients managing complex conditions, according to the PCMA's complaint. Act 624 will also lead to job losses and reduce market competition, which could cause costs to to rise for patients and their payers, the association argues. 'We will continue to fight to protect patients' access to health care and educate policymakers and stakeholders about the severe consequences of harmful legislation threatening patient access to pharmacy services,' the PCMA said in an emailed statement. The lobby's lawsuit argues that Act 624 violates the Constitution's Dormant Commerce clause and Privileges and Immunities clause by penalizing out-of-state operators to protect local businesses. The law also violates the Bill of Attainder clause, which forbids states from enacting punishments — in this case, revoking an actor's permit to conduct business — without a court proceeding, according to the complaint. The complaint makes similar legal arguments as prior lawsuits filed against Arkansas' law by CVS and Cigna, which operate two of the largest PBMs in the country: Caremark and Express Scripts, respectively. 'PCMA does not bring this suit because Act 624 is bad policy, although it very certainly is. Rather PCMA brings this suit because Act 624 is as clear an example of unconstitutional state legislation as the Court is likely ever to see,' the complaint reads. The PCMA's suit, which was filed in Arkansas' eastern district against the state's pharmacy board, seeks a preliminary injunction barring enforcement of the law while the lawsuit proceeds. Navitus Health Solutions is also a plaintiff in the suit. The Wisconsin-based PBM, which operates on a pass-through model — meaning it makes money only through administrative fees and not by retaining rebates — is not a member of the PCMA. The outcome of the suits could have significant ramifications for the PBM industry, as other states considering similar legislation could be deterred or spurred on by the court's eventual decision. Bills with similar provisions were recently introduced in Vermont, Texas and New York. States are stepping into a gap left by Congress as lawmakers scramble to make prescription drugs more affordable. Despite numerous proposals to rein in controversial PBM business practices over the past few years — including a bill that would force PBMs to sell pharmacy businesses nationwide — Congress has yet to pass significant federal reform. However, lawmakers on both sides of the aisle in Washington have expressed anger over PBMs' business practices in recent hearings. And, the GOP megabill currently being considered by the Senate includes some PBM provisions, including banning spread pricing in Medicaid, preventing PBMs from being paid based on a drug's list price and requiring more transparency about PBMs' business practices. Recommended Reading CVS, Cigna sue Arkansas to overturn new PBM law
Yahoo
29 minutes ago
- Yahoo
Backing the Future of Global Biotech: Reynold Lemkins' Strategy Across Borders and Stages
HONG KONG, June 10, 2025--(BUSINESS WIRE)--Reynold Lemkins Group, an international investment firm focused on value-driven cross-border capital deployment, announced the continued advancement of its strategic focus in late-stage healthcare, AI-powered therapeutics, and Asia-centered biotech commercialization. As part of this strategy, Reynold Lemkins recently participated in the IPO of VISEN Pharmaceuticals on the Hong Kong Stock Exchange (HKEX: 02561). VISEN, a biopharmaceutical company specializing in long-acting growth hormone therapies, attracted strong institutional demand and represents the kind of regulatory-validated, commercially scalable business the firm targets. Reynold Lemkins invested alongside globally recognized healthcare investors including HongShan Capital Group (previously Sequoia China), Sofinnova, Vivo Capital, OrbiMed, and WuXi Biologics (HKEX: 2269), reinforcing its commitment to cross-border innovation and long-term capital alignment. This investment underscores Reynold Lemkins' broader strategy of supporting science-driven, late-stage companies with scalable market potential—particularly those operating at the convergence of AI, therapeutics, and Asia-Pacific commercialization. "Our approach focuses on more than capital—we provide strategic insight and cross-border connectivity to help companies scale," said Kris Haoran Liu, President and Chief Investment Officer at Reynold Lemkins Group. "Biotech firms entering public markets need partners who understand both the science and the structure of global growth." With Asia playing an increasingly pivotal role in global healthcare, Reynold Lemkins sees a growing need for capital strategies that link scientific innovation with scalable regional execution. At the same time, the firm closely tracks trends in the U.S. and other mature markets, where biotech companies are navigating longer paths to liquidity and require strategic partners with global reach. Reynold Lemkins positions itself at this intersection—bridging East and West, public and private markets—to support companies shaping the next era of patient-centered care. To learn more, visit follow us on LinkedIn, or explore our insights on Medium. View source version on Contacts Reynold Lemkins Groupreynoldlemkins@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
32 minutes ago
- Yahoo
ZoomCare Opens New Clinic in Happy Valley
The company will host an Open House for the community on Jun. 13 PORTLAND, Ore., June 10, 2025 /PRNewswire/ -- ZoomCare, a network of neighborhood clinics serving a wide variety of healthcare needs, today announced the opening of a new clinic to serve the community of Happy Valley. The new clinic is located at 17155 SE Sunnyside Road, Suite #160 in the Happy Valley Crossroads Shopping Center. The clinic will be open seven days a week. Staffed with board-certified providers who cater to a broad range of illnesses and injuries, the Happy Valley clinic will also include preventive care services. The location features five exam rooms and offers on-site labs and prescriptions, allowing patients to leave with medications in hand. Since 2006, ZoomCare has been known for its patient experience, which is focused on compassion, quality, and efficiency. "ZoomCare believes you shouldn't have to travel far to receive excellent care," said Jeff Fee, Chief Executive Officer of ZoomCare. "We are thrilled to join the Happy Valley community. Opening this new location aligns perfectly with our mission to make healthcare easy and accessible for everyone." The company will celebrate the new clinic opening with an Open House event on Friday, Jun. 13, from 11 a.m. - 2 p.m. The Open House is open to the public and will offer free specialty coffee drinks and Italian sodas, fun giveaways, and a chance to meet the provider team and see the new clinic space. "This Open House is an excellent opportunity for our providers and clinic staff to get to know the people of Happy Valley," said Jennifer Alemany, Director of Clinical Operations in Portland. "We hope folks will come by, meet our team, and learn more about how ZoomCare can help with their healthcare needs now and in the future!" ZoomCare accepts Medicare and Medicare Advantage at all of its 47 locations in Oregon and Washington. Using Medicare-certified software platform Athenahealth, ZoomCare can access and share electronic health records with other providers and health systems. This certified software platform also lets ZoomCare establish partnerships with large health systems and insurance plans to increase patient access to primary, urgent, emergency, and specialty care. About ZoomCareZoomCare's vision is to make healthcare easy. Founded in 2006 in Portland, Oregon, ZoomCare operates more than 47 urgent, primary, emergency care, and specialty locations throughout Oregon and Washington. With conveniently located neighborhood clinics, plus evening and weekend hours, ZoomCare is committed to providing better access to healthcare and delivering evidence-based care with kindness at every visit. For more information, visit Follow ZoomCare on Facebook, Instagram, LinkedIn, and X. Media ContactAmanda Gibbs Director of Communications agibbs@ View original content to download multimedia: SOURCE ZoomCare